Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence
Clinical Investigation · 2011
DOI: 10.4155/cli.10.29 ↗At a glance
Journal article in Clinical Investigation, 2011. Written by Hendrieke C Hoftijzer and 6 co-authors. Cited 3 times so far (Crossref); 126 references.
Abstract (original language)
Differentiated thyroid carcinoma (DTC) is a highly prevalent endocrine malignancy. The majority of DTCs are slowly progressive and, when identified at an early stage, frequently cured with adequate surgical management and radioactive iodine-131 ablation therapy. Metastatic DTC that has become inoperable or refractory to radioactive iodine-131, however, is associated with a poor survival. Results of conventional treatment modalities have been disappointing and, therefore, new therapies are needed. As a result of the increasing knowledge of the biologic basis for thyroid cancer, therapeutic agents that target involved biologic abnormalities have been identified. Multiple clinical trials have been initiated and performed in the past years. In this article conventional and new treatment modalities in differentiated advanced thyroid cancer are described, with the focus on kinase inhibitors.
Cite
APA
Hoftijzer, H. C., Kapiteijn, E., Schneider, T., Hovens, G. C., Morreau, H., Gelderblom, H., & Smit, J. W. (2011). Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation. https://doi.org/10.4155/cli.10.29
Vancouver
Hoftijzer HC, Kapiteijn E, Schneider T, Hovens GC, Morreau H, Gelderblom H, et al. Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. Clinical Investigation. 2011. doi:10.4155/cli.10.29
BibTeX
@article{Hoftijzer2011,
author = {Hoftijzer, Hendrieke C and Kapiteijn, Ellen and Schneider, Tatiana and Hovens, Guido C and Morreau, Hans and Gelderblom, Hans and Smit, Johannes WA},
title = {Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence},
journal = {Clinical Investigation},
year = {2011},
doi = {10.4155/cli.10.29}
}
EUVIMED